Chlamydia trachomatis DNA (C. trachomatis DNA)

Chlamydia trachomatis DNA constitutes the entire genetic material of the obligate intracellular bacterium responsible for the most common bacterial sexually transmitted infection worldwide [1]. The genome is approximately 1.04 megabases in size and includes a highly conserved cryptic plasmid, which is frequently utilized as a primary target for diagnostic assays [2]. This DNA serves as the essential template for replication and gene expression, facilitating the pathogen's complex life cycle between infectious elementary bodies and reproductive reticulate bodies [3]. While primary treatments often target the bacterial ribosome, several classes of antibiotics, such as fluoroquinolones, act by disrupting the interaction between DNA and enzymes like DNA gyrase and topoisomerase IV, effectively halting bacterial proliferation [4]. Furthermore, the detection of C. trachomatis DNA through Nucleic Acid Amplification Tests (NAAT) remains the clinical gold standard for diagnosis due to its high sensitivity and specificity [5]. Understanding the genomic landscape of this pathogen is vital for addressing long-term complications such as pelvic inflammatory disease and infertility, as well as for monitoring the emergence of antibiotic-resistant strains [1, 6].

Other names

Chlamydia trachomatis genomeC. trachomatis nucleic acidChlamydial DNA

Inhibition of DNA replication and transcription by targeting DNA-modifying enzymes (e.g., DNA gyrase, topoisomerase IV, and RNA polymerase) that interact with the bacterial DNA template [4].